MedTrace Logo

Penetration of Ertapenem Into Bone

NCT00392028 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2007-07-13

No results posted yet for this study

Summary

The aim of the study is to determine the penetration levels of ertapenem into bone tissues in patients with Diabetes Mellitus (D.M) or Peripheral Vascular Diseases (P.V.D) undergoing amputation, and to correlate theme to the concentration of the drug in blood and other soft tissues

Conditions

  • Amputation

Interventions

DRUG

ertapenem

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • Ruth Kitzes · Clinical Pharmacology Unit, Carmel Medical Center, Haifa

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Completion
2007-07-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392028 on ClinicalTrials.gov